Alternative Therapies in Health and Medicine, 2025
Alternative Therapies in Health and Medicine, 2025
This pilot study on intravenous BPC-157 in humans found it to be safe and well tolerated. Credible early evidence but limited by small sample size and lack of replication.
Use the full description to understand the study design, methods, and the limits of the findings.
A small-scale pilot study assessing the safety and tolerability of intravenous BPC-157. Results show it is well tolerated in humans under controlled settings, though larger clinical trials are needed.
Open the original publication for the complete methods, outcomes, and source material.
The study provides preliminary evidence on the safety of BPC-157 but is limited by its small sample size and pilot nature. It lacks the robustness of larger, more comprehensive studies. While it is a credible early investigation, it should be interpreted with caution, especially for senior populations.
| Category | Score | Rating |
|---|---|---|
| Study Design / Evidence Level | 5.0/10 | |
| Bias & Methods | 6.0/10 | |
| Statistical Integrity | 5.0/10 | |
| Transparency | 7.0/10 | |
| Conflict of Interest Disclosure | 8.0/10 | |
| Replication / External Validation | 4.0/10 | |
| Relevance to Seniors | 5.0/10 | |
| Journal Quality | 7.0/10 |
Further research with larger sample sizes and specific focus on older adults is needed to strengthen the evidence base.
Review the interventions studied here and compare them against the broader treatment library.
Build a personalized plan using research-backed studies, conditions, and treatments.